Zymeworks Provides Corporate Update And Reports Third Quarter 2024 Financial Results
(MENAFN- GlobeNewsWire - Nasdaq) First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conference Our partner Jazz Pharmaceuticals …